Description of (Eculizumab)
Soliris is a humanised monoclonal antibody that is a first-in-class terminal complement inhibitor and the first therapy approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) , a rare, progressive, and sometimes life-threatening disease.
Its use and Indications
Soliris is indicated for
- The treatment of patients of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
- The treatment of patients with atypical haemolytic uremic syndrome (aHUS) to inhibit complement- mediated thrombotic microangiopathy.
For treatment related information, please consult your treating Physician.
Soliris is supplied as 300 mg single-use vials each containing 30 ml of 10 mg/ml sterile, preservative-free eculizumab solution.
Storage and handling
Soliris vials must be stored in the original carton until time of use under refrigerated conditions at 2-8°C and protected from light.
DO NOT FREEZE, DO NOT SHAKE
How do we source the Drug?
Super Specialities Pharma will assist in sourcing the drug through its efficient network, across the globe, and ensure the delivery is prompt. However, a valid prescription from the treating Oncologist is mandatory, with all relevant documents associated with its procurement is essential.
Company that Manufactures/ Markets:
M/s Alexion Pharmaceuticals, Inc.,
Mob No: +91 7738100125, +91 7738151650
E Mail: firstname.lastname@example.org